Otonomy reports positive results with hearing loss candidate
A former Novo Ventures-owned biotech firm, Otonomy, has announced that a full phase II trial of its hearing loss drug candidate will take place this year after having just publicized positive results from a preceding phase IIa study.
by christian bundgaard, translated by daniel pedersen
Biotech firm Otonomy, listed in the US, has scored its first top-line results from clinical studies of the candidate OTO-413, a potential hearing loss treatment, the company reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Hearing Industries Association calls for more OTC regulation
For subscribers
